Adocia (Euronext Paris: ADOC) has announced that American drugmaker Eli Lilly (NYSE: LLY) has terminated an agreement to develop and commercialize the fast-acting insulin treatment BioChaperone Lispro.
As European markets reacted to the news, shares in Adocia fell off a cliff, and are now down nearly 30% since the opening bell.
It’s the second time Lilly has walked out on the French biotech firm.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze